French surgeons call off London protest:
This article was originally published in Clinica
London will not be playing host to the mutinous French surgeons next week after all (see Clinica No 1120, p 4) as the French government has hurriedly acquiesed to a series of its demands It has agreed to set aside E60m ($74m), equivalent to E15,000 for each surgeon, to pay for an increase in surgical procedure tariffs which will apply from October 1. It will also commit the sickness insurance association to part-finance a higher share of the surgeons' escalating insurance costs, a measure costing some E20m. Further discussions concerning the contractual arrangements between the surgeons and the French healthcare service will be held in the autumn.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.